GHRP-2 side effects and safety context

At diagnostic doses GHRP-2 is unremarkable — the test is described in the clinical literature as convenient and safe, and a 30-day continuous infusion in healthy older adults left safety screening tests normal throughout (Bowers et al., J Clin Endocrinol Metab 2004). Two effects are nonetheless well documented and matter for how the compound is actually used: it substantially increases food intake, and it activates the hypothalamic-pituitary-adrenal axis strongly enough to be usable as a cortisol stimulation test. Neither is a rare adverse event; both are the drug working.

In a controlled crossover study, seven lean healthy men receiving GHRP-2 at 1 µg/kg/h subcutaneously for 270 minutes ate 35.9 ± 10.9% more at a subsequent buffet meal than on saline — 32.5 versus 24.2 kcal/kg (p = 0.008) — choosing the same macronutrient mix, just more of it (Laferrère et al., J Clin Endocrinol Metab 2005).

This is a direct consequence of the mechanism. GHRP-2 is a synthetic agonist at the growth hormone secretagogue receptor, the same receptor ghrelin uses, and ghrelin's day job is signalling hunger. Anyone using GHRP-2 alongside a calorie deficit is running two opposing interventions. Whether the effect counts as a side effect or a therapeutic action depends on why it is being taken.

Older growth hormone releasing peptides are described as "less selective" than ipamorelin, which is often left as a vague claim. For GHRP-2 it can be quantified, because clinicians deliberately exploit it. In 15 patients investigated for hypopituitarism, a 100 µg intravenous dose of GHRP-2 produced a median peak cortisol of 21.4 µg/dL in those with normal adrenal function versus 11.4 in those with confirmed HPA-axis failure, with peak cortisol correlating strongly with the insulin tolerance test (r = 0.817, p < 0.0001) (Kano et al., Peptides 2010).

A compound that raises cortisol to insulin-tolerance-test levels is not hormonally silent. The effect appears to be indirect — animal work indicates GHRP-2 acts through the hypothalamus, with ACTH release mediated mainly by corticotropin-releasing factor rather than by any direct pituitary action (Hirotani et al., Naunyn Schmiedebergs Arch Pharmacol 2005). The same class effect was seen in the earliest human GHRP work, where prolactin and cortisol rose about two-fold above baseline at the highest dose tested (Bowers et al., J Clin Endocrinol Metab 1990).

Note the dose dependence: these are effects of larger stimulation doses, and what happens to cortisol across weeks of smaller repeated doses has not been published.

The GH response attenuates. Over 30 days of continuous subcutaneous GHRP-2 in 17 healthy older adults, GH secretion was stimulated more than three-fold on day 1 but only about 1.8-fold by days 14 and 30, while IGF-1 held a stable plateau (Bowers 2004). Reviews of the class describe this as partial desensitisation — more pronounced during continuous infusion, less during intermittent administration (Ghigo et al., Eur J Endocrinol 1997).

Diminishing effect is not itself dangerous. It becomes a safety issue when it prompts dose escalation into ranges no study has examined.

Anything that reliably raises GH and IGF-1 carries the concerns printed on approved growth hormone labels: glucose intolerance, fluid retention, intracranial hypertension, and neoplasm risk. A review of growth hormone secretagogues found them generally well tolerated but singled out increases in blood glucose driven by decreased insulin sensitivity, and called explicitly for evaluation of cancer incidence and mortality with long-term use (Sigalos & Pastuszak, Sex Med Rev 2018).

The longest human dataset in the class comes from a different molecule: two years of oral MK-677 in 65 healthy older adults raised fasting glucose by about 5 mg/dL, lowered insulin sensitivity, and produced increased appetite, transient mild lower-extremity oedema and muscle pain as the most frequent complaints (Nass et al., Ann Intern Med 2008). Those are the effects to expect from a GHS-R agonist used for long enough to matter.

• Chronic subcutaneous dosing in healthy adults — the longest published exposure is 30 days, by continuous infusion, in 17 people.
• Carcinogenicity — no long-term study addresses it for this compound.
• Product quality — material sold outside a pharmacy supply chain carries no verified identity, purity, aggregate or endotoxin data, and those attributes drive immunogenicity risk in an injected peptide.

GHRP-2 is also prohibited in sport at all times under WADA section S2, and is detectable — as parent compound and metabolites — in urine for up to 47 hours after administration (Semenistaya et al., Drug Test Anal 2015).

See also GHRP-2 benefits and dosing education.